FluGen Inc., a Madison company developing a new flu vaccine and a new way of delivering vaccines, hopes to raise $3 million for the next phase of a clinical trial.
Yet the company can't turn to the state-backed venture capital fund created last year to spur economic development, because the Legislature barred the fund from investing in many biotechnology companies. The ban was pr
